查看文章

Purpose: PReferentially expressed Antigen in MElanoma (PRAME) immunohistochemistry (IHC) is a valuable diagnostic tool and prognostic marker in the evaluation of cutaneous melanomas. Recently, strong nuclear PRAME IHC labeling was found to help distinguish malignant from benign conjunctival melanocytic lesions (CMLs)(PMIDs: 20805128, 34268800, 34089198). To corroborate these findings, we performed a retrospective study of PRAME IHC staining patterns in previously biopsied CMLs at our institution.

Methods: CMLs were obtained from 16 patients who underwent biopsy of conjunctival lesions. IHC was performed to evaluate for melanocytic differentiation (MelanA, HMB-45, or SOX-10) and nuclear PRAME expression. Patient demographics, lesion characteristics, and PRAME status by IHC were included in the retrospective cohort analysis.

Results: The cohort of 16 patients included 11 females and …